Register for our free email digests:
Investor Eye
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Investor Eye: Claudio D’Angelo Of RYSE Asset Management Explains Early-Stage Digital Health Investment
RYSE head tells Medtech Insight about his firm’s shift to investing in virtual primary care and telemedicine.
Latest From Investor Eye
Investor Eye: Kyp Sirinakis, Epidarex Capital – ‘The Innovation Hunter’
In this edition of Investor Eye, Medtech Insight spoke to Kyp Sirinakis, managing partner at Epidarex Capital, a transatlantic fund investing in emerging life science hubs in the US and UK. The firm recently launched a new UK fund, Epidarex Capital III, for innovative UK start-ups.
Investor Eye: Sergey Young Searches For Investments That Extend Life
Sergey Young is on a mission to "extend healthy lifespans" by investing in longevity breakthroughs. Last year, the venture capitalist established a $100m fund investing in technologies with the potential to improve healthy long living.
Investor Eye: Howard Rowe, Hayfin Capital Management – The Specialized Health Care Lenders
In this edition of Investor Eye, Medtech Insight meets with Howard Rowe, managing director and head of health care at Hayfin Capital Management, a $17bn international asset management firm headquartered in London.
Investor Eye: Israel’s Medical Device Fund Accelmed Seizes On Slow Medtech Investing
Israeli healthtech fund Accelmed is seizing the opportunity to implement a medtech-investment strategy that is delivering big returns. In this Medtech Insight feature, Irit Yaniv, partner at Israeli VC Accelmed, discusses changing trends in the medtech VC industry and the hot new areas of medical technology coming out of Israel.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.